Effects of therapy with trimetazidine in ischemic heart disease by Jukić, Tena
UNIVERSITY OF ZAGREB 
SCHOOL OF MEDICINE  
 
 
Tena Jukić  
 
 
 
Effect of therapy with trimetazidine in 
ischemic heart disease 
 
 
 
 
 
 
 
 
GRADUATE THESIS 
 
Zagreb, 2016 
 
UNIVERSITY OF ZAGREB 
SCHOOL OF MEDICINE  
 
 
Tena Jukić  
 
 
 
Effect of therapy with trimetazidine in 
ischemic heart disease 
 
 
 
 
 
 
 
 
GRADUATE THESIS 
 
Zagreb, 2016 
 
This graduation paper was made at the Department of Cardiology, KBC Rebro, 
University of Zagreb School of Medicine under the supervision of Prof. dr.sc. Martina 
Lovrić-Benčić and it was submitted for evaluation in the academic year 2015/2016. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
 
IHD – Ischemic heart disease 
PCI – Percutaneous intervention 
CABG – Coronary artery bypass graft 
LV- Left ventricle 
MET- Metabolic equivalent of task 
VES- Ventricular extrasystole 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents 
Summary…………………………………………………………………………………… 
Introduction………………………………………………………………………………1 
Hypothesis……………………………………………………………………………......14 
Material and Methods………………………………………………………………..…..15 
Results……………………………………………………………………………...…….19 
Discussion…………………………………………………………………………..……23 
Conclusion…………………………………………………………………………..…...26 
Acknowledgements………………………………………………………………………27 
References…………………………………………………………………………..……28 
Biography……………………………………………………………………………...…34 
 
 
 
 
 
 
 
 
 Summary 
Title: Effect of Trimetazidine in Ischemic Heart Disease 
Key words: Ischemic heart disease, trimetazidine 
Author: Tena Jukić 
 
In the developed world, IHD is the leading cause of death in both sexes, 
accounting for 30% of all deaths. Because of that high mortality rate, it becomes a really 
important topic of not just public health, but also every part of human society including 
economics, food industry, health industry etc.  
Myocardial ischemia refers to inadequate supply of oxygen and metabolic 
substrate to the heart. The term myocardial ischemia covers a heterogeneous group of 
clinical syndromes, globally called IHD, which includes chronic stable angina at one end 
of the spectrum and acute myocardial infarction at the other end. 
Clinical approach is an important factor in diagnosing IHD. Diagnosis is 
suspected if chest discomfort is typical and is worsening by exertion and relieved by rest. 
Some specific test include ECG, stress test ECG, echocardiography, radionuclide 
imaging and coronary angiography. Treatment depends on the severity of the angina pain, 
mostly it is treated with drugs like antiplatelet drugs, beta blockers, long-acting nitrates 
and calcium channel blockers. In severe cases, i.e. if angina persists despite drug therapy, 
PCI and CABG will be indicated. 
In patients who are not PCI or CABG candidates, or are not responding well on the 
normal drug treatment, are very good candidates for trimetazidine. Trimetazidine is a 
drug which acts on mitochondrial level and shifts cardiac metabolism.
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Introduction 
Nowdays, IHD is an inevitable world wide social and medical problem. In 
developed countries it is a leading cause of death, although the mortality rate is 
significantly decreased in past three decades. Therefore prevention of disease is a 
challenge not just for specialized medical doctors, also for the society. 
IHD is presence of clinical symptoms that are present due to myocardial ischemia 
which is a consequence of changes in coronary circulation and disproportion in 
myocardial oxygen need and utilization. Diagnosis of IHD includes those who are 
atherosclerotic and non-atherosclerotic in origin. 
IHD is most common cause of death in developed countries and causes more 
deaths and economic loses then any other known disease. According to Croatian 
statistics, there is a slight increase in IHD, unlike USA and other developed countries 
which have a decrease in IHD which is possible due to good public health actions and 
promotion and implementation of primary and secondary prevention. In any age group 
there is a higher prevalence in male gender (4:1). 
Atherosclerosis of coronary arteries with or without superimposed thrombus is 
most common cause of IHD. The ground lesion is atherosclerotic plaque which can be 
stabile, activated and ruptured. Therefore patients will have different clinical picture of 
IHD. In younger population, some other diseases  can cause ischemia like congenital 
anomalies of coronary arteries. In eldery population, ischemia can be caused by some 
connective tissue diseases like systemic lupus. Other possible causes are coronary arteries 
emboli (especially in patients with atrial fibrillation). Spasm of  healthy coronary artery 
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can also be one of the causes of ischemia. Most common noncoronary cause of ishemia 
are nonregulated arterial hypertension, aortic stenosis and hypertrophic cardiomyopathy 
(1). 
The most common symptom of IHD is angina. Angina can be described as a chest 
tightness, pressure, aching, burning, squeezing or painful feeling. Sometimes it can be 
mistaken for  heartburn. Angina is usually felt in the chest, but can spread to the 
left shoulder, arms, neck, back, or jaw. Other symptoms that can occur include: shortness 
of breath (especially in exertion), palpitations, weakness, dizziness, nausea, sweating (2). 
Risk factors include: dyslipidemias; particularly high low density cholesterol (LDL-C) 
and low high density cholesterol (HDL-C), hypertension, diabetes mellitus, smoking 
(most important modifiable risk factor), family history of premature coronary artery 
disease, obesity, male sex and advanced age etc (3, 4). 
Numerous primary and secondary prevention trials have shown that aggressive 
management of modifiable risk factors reduces death rates, myocardial infarction, stroke, 
and other cardiovascular events, including the need for revascularization. A 1-mm Hg 
decrease in blood pressure lowers the long-term risk of MI by 2% to 3%, whereas a 10% 
reduction in LDL cholesterol diminishes cardiovascular death by 10% and cardiovascular 
events by 25%. Similarly, smoking cessation reduces the attendant cardiovascular risk. 
Diabetes mellitus and metabolic syndrome elevate the risk of cardiovascular death 2- to 
4-fold and reduce life expectancy by 5 to 10 years. The National Cholesterol Education 
Program Adult Treatment Panel III report has defined and recently refined guidelines for 
the primary and secondary prevention of atherosclerosis on the basis of risk scales that 
3 
 
account for blood lipids, modifiable and nonmodifiable nonlipid risk factors, and other 
emerging risk factors (5). 
Lifestyle measures must remain the foundation for the primary prevention of 
cardiovascular disease. However, individuals whose risk of cardiovascular events 
exceeds 2%/y and patients with CAD or CAD equivalents often also merit drug therapy. 
The Heart Protection Study showed unambiguous benefit of statin administration in 
individuals aged 40 to 80 years with total cholesterol >135 mg/dL and at risk because of a 
previous myocardial infarction or other coronary or noncoronary artery occlusive disease, 
diabetes mellitus, or treated hypertension (6). The Physicians’ Health Study showed that 
aspirin significantly reduced the rates of myocardial infarction in men aged 40 to 80 years 
(7). The Heart Outcomes Prevention Evaluation study enrolled patients 55 years of age or 
older with evidence of vascular disease or diabetes plus 1 other cardiovascular risk factor 
randomized to the angiotensin-converting enzyme inhibitor ramipril or placebo (8), and 
the European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary 
Artery Disease studied the effects of perindopril in patients with stable CAD of a lower-
risk category (9). Both studies showed that ACE inhibitor administration significantly 
reduced cardiovascular events. A recent trial in a lower-risk population showed no 
advantage of ACE inhibitor therapy over contemporary conventional management, 
highlighting the role for lifestyle modification in such individuals (10). 
Diagnosis is suspected if chest discomfort is typical and precipitated by exertion 
and relieved by rest. One of the most common and first diagnostic tool that is used for 
diagnosing IHD is a stress test. Cardiac stress test is done by heart stimulation (treadmill, 
pedaling stationary bicycle or pharmacological stimulation) an the physician examines 
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the symptoms, blood pressure response and ECG changes. Coronary angiography is the 
standard for diagnosing IHD but is not always necessary to confirm diagnosis (11). 
Intravascular ultrasonography enables us coronary artery structure images. Definitely 
worth of mentioning is coronary CT. CCTA doesn’t show only lumen of coronary 
arteries (as invasive coronary angiography) but also provides other cardiac structures as 
large blood vessels and coronary arteries which helps evaluate complex variants of 
coronary arteries, coronary bypass, myocardial bridging, coronary arterial fistulas, aortic 
dissection and coronary arteries dissection (12). 
Current medical therapies for IHD involve anticoagulants, thrombolytic, beta 
blockers, calciun channel blockers, nitrates and percutaneous coronary intervention 
which aim to improve the blood supply of the heart (11). However, these treatments will 
irreversibly cause myocardial ischemia/reperfusion injury. Over the last 30 years, 
researches demonstrate that partial inhibition of myocardial fatty acid oxidation, with 
mutual activation of carbohydrate oxidation, is an effective treatment for 
ischemia/reperfusion injury (13). 
When oxygen supply is decreased, the oxidative processes of free fatty acids and 
glucose are impaired, what will lead to an increased rate beta oxidation of free fatty acids 
associated with even greater oxygen consumption—while glucose metabolism decreases, 
which results in lactate accumulation and, in extreme cases, development of metabolic 
acidosis (14, 15). 
Myocardial ischemia is responsible for angina, unstable angina, and shortness of breath 
secondary to ischemic left ventricular dysfunction as well as cardiac arrhythmias.  
 
5 
 
Myocardial oxygen demand 
Organs that are very oxidative such as the heart have a high demand for oxygen 
and therefore have a relatively high oxygen consumption. Myocardial oxygen 
consumption (MVO2) is required to regenerate ATP that is utilized by membrane 
transport mechanisms (Na+/K+-ATPase pump) and by myocyte contraction and relaxation 
(myosin ATPase) .  
 
Cardiac State 
MVO2 
(ml O2/min per 100g) 
Arrested heart 2 
Resting heart rate 8 
Heavy exercise 70 
Table 1:Myocardial oxygen demand 
 
Determinants of myocardial oxygen consumption (MV̇O2) are myocardial mass, 
myocardial work (heart rate, blood pressure), precontraction tension (left ventricle size) 
and inotropic status (16). 
Oxygen delivery to the myocardium depends upon oxygen carriage by the blood 
and coronary blood flow. Oxygen carriage by the blood can be disrupted by a fall in 
hemoglobin, and a sudden worsening of symptoms of angina in a patient who has been 
stable for many months or years may often be explained by the development of anemia. 
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Indeed, in patients with severe coronary disease a pronounced and rapidly acquired 
anaemia may induce ischaemia to such a degree that subendocardial infarction may 
ensue.  
 
Pathophysiology 
As the myocardium becomes ischemic, coronary sinus blood pH falls, potassium 
in the cell is lost, lactate becomes more abundant, abnormal changes in ECG appear, and 
ventricular function (both systolic and diastolic) happens. LV diastolic pressure usually 
increases during angina, sometimes inducing pulmonary congestion and dyspnea. The 
exact mechanism by which ischemia causes discomfort is unclear but may involve nerve 
stimulation by hypoxic metabolites. 
Atherosclerosis in the conduit, has its effect by disrupting the coronary 
physiology, and the introduction of a new resistance to coronary flow. This acquired 
resistance is in series with the physiological resistors and thus has its impact on coronary 
flow reserve reducing this on occasions to levels not allowing sufficient oxygen delivery 
to the myocardium. 
Atherosclerotic epicardial plaques have a complex relation to coronary resistance. Some 
of these (20–30%) are dynamic, although within a reasonably small range of reactivity 
where exercise or constricting agents may induce a 20% reduction in the stenosis 
diameter. Others, however, appear to be fixed. In addition, the longer the coronary lesion 
the greater the resistance and, of course, two lesions in parallel add further to stenosis 
significance. 
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The assessment of the relation between the degree of epicardial coronary 
narrowing and the measured coronary flow reserve is complex. Within instrumented 
animals the classic work of Gould and Lipscomb in the 1970s suggests that a stenosis in a 
conduit vessel of less than 50% is unlikely to be of hemodynamic significance (17).  For 
stenoses with luminal narrowing greater than 50% there is a complex and curvilinear 
relation to the reduction in maximum coronary flow. Lesion length also affects the 
coronary flow reserve, with longer lesions producing greater haemodynamic changes 
(18). 
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Evaluation of coronary stenosis and influence on coronary flow 
 
Evaluation of patients by angiography have shown a very loose relation between 
the level of coronary narrowing and coronary flow reserve (19, 20). However, the use of 
positron emission tomography (PET) scanning to measure coronary flow reserve has 
increased ability to measure this difficult parameter accurately under basal conditions in 
humans (21). These studies have confirmed a complex relation, curvilinear, between 
coronary stenosis diameter and coronary flow reserve, but it should be noted that the 
individual points for patients studied show remarkable scatter around any statistically 
defined relation. Nonetheless the PET data would not wildly disagree with the animal 
data indicating that stenoses less than 50% in diameter are unlikely to be of functional 
haemodynamic significance. 
The advent of intracoronary wires able to carry Doppler and pressure transducers 
has allowed cardiologists to “interrogate” epicardial coronary stenoses that appear to be 
of borderline significance. Broadly, however, these devices all rely on the induction of 
maximal hyperemia with a microvascular vasodilating drug (usually adenosine) 
administered either intravenously or intracoronary. Devices either record the change in 
coronary blood velocity (Doppler wires) or measure the pressure gradient induced across 
the lesion (pressure wires, RADI). Doppler wires, because of technical considerations and 
the influence of side branches and the variability of signal if moved, have been largely an 
experimental tool. The pressure wire appears more stable and is easier to use. The 
important work of Pijls in this area has suggested that a ratio of mean distal coronary 
blood pressure to mean proximal coronary blood pressure following maximum 
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hyperaemia of less than 0.75–0.8 indicates a stenosis that is of functional significance 
(19). 
 
Trimetazidine 
 
Percutaneous or surgical revascularization are these days the best options to 
enhance myocardial blood flow. However in some patients none of these two options are 
accetable and the medicament therapy which is usually consisting of beta blockers, 
calcium channel blockers and/or nitrates is not enough. Some drug had to be introduced 
at the level of metabolic pathways in ischemic myocardial cells, especially in those 
patients for whom optimal control of symptoms cannot be achieved with other 
antianginal drugs.  
Trimetazidine is a drug used for angina pectoris and it seems to provide anti-
ischemic effect by preserving energy balance and prevent changes in ion homeostasis 
during ischemia due to modulatory effects on intracellular calcium. It also has action that 
stimulates glucose oxidation and acts as a partial fatty acid oxidation inhibitor through a 
reduction of the mitochondrial activity of 3-ketoacyl coenzyme A thiolase (enzyme that 
catalyzes the terminal step of fatty acid β-oxidation). In this manner trimetazidine can  
shift cardiac energy metabolism from fatty acid oxidation to glucose oxidation (22). 
Mitochondrial matrix is the place where fatty acid oxidation and pyruvate oxidation both 
occur and have common substrates and products. Suppression of myocardial fatty acid 
oxidation lowers the mitochondrial ratios of NADH/NAD+ and acetyl-CoA/free CoA, 
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which relieves inhibition on pyruvate dehydrogenase (PDH) and increases glucose and 
lactate oxidation (23). However, the detailed mechanism has not been clarified yet. 
 
Cardiac metabolism 
 
The human heart must contract all the time, thus, the requirement for energy to 
fuel optimal function is very important. The heart is capable of using all energy 
substrates, including carbohydrates, lipids, amino acids, and ketone bodies, which are 
necessary for ATP production in the mitochondria (24, 25). In cardiac myocytes, 
mitochondria are possessing one third of cardiac cells, which makes them the cell type 
with the highest mitochondria content (26). As it is known that fatty acids are the 
predominant substrate used in the adult myocardium. However, the cardiac metabolic 
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network is highly flexible in using other substrates when they become abundantly 
available.  
Fig. 1: Overview of the metabolic network. The energy-yielding substrates (fatty acids, 
glucose, ketones, and amino acids), via specific catabolic pathways, converge on acetyl-
CoA production with subsequent entry into the tricarboxylic acid (TCA) cycle.  
 
For example, cardiac extraction and oxidation of lactate becomes predominant 
during exercise as skeletal muscle lactate production increases (27 , 28). However, 
cardiac metabolism changes as oxygen supply to myocardium becomes limited, which 
leads to decreased energy production through beta-oxidation of fatty acids and glucose 
oxidation, as well. As a major source of energy becomes anaerobic glycolysis. Validity of 
cardiac metabolism is reflected by its highest oxygen consumption rate on the per unit 
weight basis. For a human heart, the amount of ATP turned over during a 1-day period is 
15 to 20 times of its own weight. In a normal heart, mitochondria are largely fueled by 
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fatty acyl-coenzyme A (CoA) and pyruvate, which are the primary metabolites of fatty 
acids and carbohydrates, respectively. The entry of long-chain acyl-CoA into the 
mitochondria is a regulated process, with the rate-limiting step at the muscle form of the 
carnitine-palmitoyl transferase-1 (CPT1) reaction. The oxidation of pyruvate is regulated 
at the pyruvate dehydrogenase (PDH) reaction. Other substrates, including lactate, ketone 
bodies, and amino acids, can enter mitochondria directly for oxidation. Metabolism of 
ketone bodies yields acetyl-CoA, whereas amino acid catabolism yields keto-acids, which 
are further metabolized to enter the tricarboxcylic acid cycle. The contribution of ketone 
bodies and amino acids to overall cardiac oxidative metabolism is considered to be minor 
because of the low availability of these substrates under normal physiological conditions. 
 
Fig. 2: Overview of fatty acid beta oxidation in the heart 
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Apart from substrate availability, complex regulatory mechanisms contribute to 
metabolic flexibility at multiple levels, including transcriptional regulation and post-
translational modification of key proteins involved in each metabolic pathway as well as 
allosteric regulation by substrates and their metabolites. Transcriptional regulation of the 
proteins involved in fatty acid oxidation (FAO) by the peroxisome proliferator–activated 
receptor (PPAR)/estrogen-related receptor/PPARγ coactivator-1 α (PGC1α) circuit is a 
major mechanism in the transition of the glycolysis-dependent fetal heart to oxidative 
metabolism in the adult heart (29, 30). 
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Hypothesis 
By administration of trimetazidine 35 mg twice a day we expect to have: 
- decrased number of VES 
- ST segment closer to the isoelectric point  
- improvement in MET results 
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Material and methods 
 
To examine association between effect of trimetazidine in IHD we referred them 
for a stress test and analyzed their results in a fashion to create categories. Categories are 
made by age, younger and older then 65, gender, diabetic and non-diabetic patients, and 
patients distributed in 3 EF groups: those who had EF <40%, 40-50%, and > 50% . Data 
was obtained from KBC Rebro. The data that was relevant to us was incorporated into an 
excel spreadsheet which was then analyzed. Microsoft excel was used to organize and 
evaluate parts of the data, such as grouping into male and female and further into age 
groups with appropriate EF values, metabolic equivalents from stress test before and after 
therapy and number of VES also captured by 24 hour Holter monitoring. We had 82 
patients (53 men and 29 women, mean age 61.6 years, SD 9.11) with ischemic heart 
disease and left ventricular dysfunction who were followed at KBC Rebro outpatient 
department. Trimetazidine was given to a patients 35mg, twice a day.  
Trimetazidine has been in clinical use for more than two decades. It is a very 
useful and potential drug for treatment of several conditions like systolic dysfunction in 
cardiac failure patients. In vivo and in vitro studies have shown that in ischemia, 
trimetazidine has a specific effect: reduces intracellular acidosis, inhibits accumulation, 
maintains intracellular ATP levels, decreases kreatinine kinase release an preserves 
myocardial function (14). Several studies reveal that patients who were taking 
trimetazidine experienced less angina episodes and had longer interval period onset in 
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stress test compared to patients treated with other anti-anginal drugs or they were 
consuming placebo (31). 
 
Fig.3:Age distribution 
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Chart 1: Gender ratio 
 
 
Chart 2: Age groups 
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Chart 3: Diabetics 
 
 
Chart 4: EF values 
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Results 
 
All of them received trimetazidine dihydrocloridum 35 mg twice daily. After 6-12 
months of follow-up, they repeated exercise testing, and had 24 hour Holter monitoring. 
The results were compared according to diabetes, sex, age and ejection fraction. 
Statistics: Wilcoxson rank test. 
 
 
Analyzing MET values for total sample, results showed significat improvement on stress 
test after therapy with trimetazidine. 
Comparison of MET values for total sample, before and after trimetazidine: 
Ranks 
 N Mean Rank Sum of Ranks 
Erga after (MET) - Erga before 
(MET) 
Negative Ranks 0a .00 .00 
Positive Ranks 82b 41.50 3403.00 
Ties 0c   
Total 82   
 
a. Erga after(MET) < Erga before (MET) 
b. Erga after (MET) > Erga before (MET) 
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c. Erga after (MET) = Erga before (MET) 
 
Test Statisticsa 
 
Erga after (MET) 
- Erga before 
(MET) 
Z -7.878b 
Asymp. Sig. (2-tailed) .000 
 
a. Wilcoxon Signed Ranks Test 
b. Based on negative ranks. 
 
Deviations of ST values for total sample, before and after trimetazidine: 
Ranks 
 N Mean Rank Sum of Ranks 
Erga ST after - Erga ST before Negative Ranks 24a 13.71 329.00 
Positive Ranks 2b 11.00 22.00 
Ties 56c   
Total 82   
 
a. Erga ST after < Erga ST before 
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b. Erga ST after > Erga ST before 
c. Erga ST after = Erga ST before 
 
Test Statisticsa 
 
Erga nakon 
(MET) - Erga 
prije (MET) 
Z -7.878b 
Asymp. Sig. (2-tailed) .000 
 
VES number comparison before and after trimetazidine: 
 
Ranks 
 N Mean Rank Sum of Ranks 
VES Holter after - VES Holter 
before 
Negative Ranks 66a 46.89 3094.50 
Positive Ranks 16b 19.28 308.50 
Ties 0c   
Total 82   
 
a. VES Holter after < VES Holter before 
b. VES Holter after  > VES Holter before 
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c. VES Holter after = VES Holter before 
 
Test Statisticsa 
 
VES Holter after - 
VES Holter 
before 
Z -6.440b 
Asymp. Sig. (2-tailed) .000 
 
a. Wilcoxon Signed Ranks Test 
b. Based on positive ranks. 
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Disscusion 
Patients who are diagnosed with IHD and cannot undergo procedure such as 
catheterization, or are not well controlled in terms of angina pain by using standard 
medication for angina (beta blockers, calcium channel blockers, nitrates) are very good 
candidates for taking trimetazidine. Trimetazidine has been in clinical use for more than 
20 years and since then has been a lot of researches on that topic that are proving the 
effectiveness of trimetazidine in IHD. One also says that trimetazidine can reduce 
myocardial infarction size through AMPK and ERK signaling pathways (32). 
Trimetazidine exerts its protective effect via both AMPK signaling pathway as well via 
regulating ERK pathway. The role of AMPK is regulation of lipids oxidation in 
myocardial cells by inactivating acetyl-CoA carboxylase (ACC) and reducing malonyl-
CoA levels, which as a consequence, increase CPT-I activity and mitochondrial lipid 
oxidation (33, 34). 
Clinical studies comparing trimetazidine with placebo or reference anti-ischemic 
drugs as well as in combination with other anti-ischemic agents have been performed 
(35). Studies comparing trimetazidine and placebo: The acute effects of a single oral dose 
of 60 mg trimetazidine were evaluated in a double-blind, placebo-controlled, crossover 
study by Sellier et al.(36). Two hours after oral intake, the mean total work performed by 
patients treated with trimetazidine was 30% greater than that performed by patients 
treated with placebo. Time to 1-mm ST segment depression was significantly longer in 
the trimetazidine-treated patients than in the placebo group. Two double-blind, placebo-
controlled studies (37, 38) with a similar design have evaluated the effects of 
trimetazidine in patients suffering from chronic stable angina. In both studies, an exercise 
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test was performed at the beginning and at the end of a 2-week preselection period to 
verify the stability of ischemic parameters. Subsequently, the patients were randomized 
to receive either trimetazidine 20 mg 3 times daily or placebo 3 times daily for 1 month 
and at the end of the study period a final exercise test was conducted. Passeron11 
documented an increase in total workload of 62% in patients treated with trimetazidine 
and 25% in patients receiving placebo. There was a significant reduction in the number of 
angina attacks per week in trimetazidine and placebo group. 
The greatest progress in the use of metabolic therapy came in the last 15 years 
with the advent of compounds that partially inhibit myocardial fatty acid oxidation, 
specifically trimetazidine (1-[2,3,4-trimethoxibenzyl]- piperazine) and ranolazine, for the 
treatment of chronic stable angina pectoris (39). 
Improvement of ischemic regional myocardial dysfunction at rest and during 
stress-induced ischemia in patients with chronic coronary artery disease, was also proven 
by one study that demonstrated administration of trimetazidine without affecting the 
hemodynamic determinants of myocardial oxygen consumption in patients with coronary 
artery disease (40). 
From the other hand there was a study which was using objective (stress test 
parameters) and subjective (questionnaire) values to evaluate the effect of trimetazidine, 
comparing results of both. In this research mean workload before starting therapy with 
trimetazidine was 6.5 METs and after was 6.8 METs. The difference of 0.3 MET is 
statistically significant (p<0.03). 
From the KBC Rebro experience, starting the therapy with trimetazidine 35mg 
twice a day to the patients with ischemic heart disease provided a great results: 
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improvements in functional capacity, better results in exercise testing (significant 
increase in METs, as it is shown in our results all of 82 patients had better METs after 
administration of trimetazidine) , less ventricular premature beats regardless of age, sex 
or diabetes (in 66 patients out of 82). The effect of trimetazidine on  glucose oxidation 
optimizes cellular energy processes, thereby maintaining proper energy metabolism 
during ischemia. By preserving energy metabolism in cells exposed to hypoxia or 
ischemia, trimetazidine prevents a decrease in intracellular ATP levels, thereby ensuring 
the proper functioning of ionic pumps and transmembrane sodium-potassium flow whilst 
maintaining cellular homeostasis,  which is indirectly confirmed with our results. 
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Conclusion 
 
In conclusion I can say that our results shows that we proved our hypothesis. 
Trimetazidine indeed provided anti-ischemic effect by preserving energy balance and 
prevent changes in ion homeostasis. It also has action that stimulates glucose oxidation 
and acts as a partial fatty acid oxidation inhibitor. Our results showed that trimetazidine 
has significant effect in our variables: 
-  Less anginal problems after administration of trimetazidine 
- ST segment was closer to the isoelectric line  
- Decrease in ventricular extrasystole activity 
Trimetazidine is a very valuable drug in a treatment of IHD, especially when standard 
treatments as PCI and CABG aren't sufficient, therefore it's action plays a significant role 
in treatment of IHD. 
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